Economic Evaluation of Voriconazole for the Treatment of Candidemia in Canadian Adults
BACKGROUND: Candidemia is a common cause of nosocomial bloodstream infection. When selecting therapeutic treatments for candidemia, cost-effectiveness is an important consideration. The present study assessed the cost-effectiveness of voriconazole for the treatment of candidemia.
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2008-01-01
|
| Series: | Canadian Journal of Infectious Diseases and Medical Microbiology |
| Online Access: | http://dx.doi.org/10.1155/2008/161835 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832546955832590336 |
|---|---|
| author | Coleman Rotstein Lael Cragin Michel Laverdière Gary Garber Eric J Bow Alissa Scalera Craig Roberts Sonja V Sorenson the Canadian Expert Panel |
| author_facet | Coleman Rotstein Lael Cragin Michel Laverdière Gary Garber Eric J Bow Alissa Scalera Craig Roberts Sonja V Sorenson the Canadian Expert Panel |
| author_sort | Coleman Rotstein |
| collection | DOAJ |
| description | BACKGROUND: Candidemia is a common cause of nosocomial bloodstream infection. When selecting therapeutic treatments for candidemia, cost-effectiveness is an important consideration. The present study assessed the cost-effectiveness of voriconazole for the treatment of candidemia. |
| format | Article |
| id | doaj-art-8269efadbea5430cb492e010501198a2 |
| institution | Kabale University |
| issn | 1712-9532 |
| language | English |
| publishDate | 2008-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Canadian Journal of Infectious Diseases and Medical Microbiology |
| spelling | doaj-art-8269efadbea5430cb492e010501198a22025-02-03T06:46:26ZengWileyCanadian Journal of Infectious Diseases and Medical Microbiology1712-95322008-01-0119321922610.1155/2008/161835Economic Evaluation of Voriconazole for the Treatment of Candidemia in Canadian AdultsColeman Rotstein0Lael Cragin1Michel Laverdière2Gary Garber3Eric J Bow4Alissa Scalera5Craig Roberts6Sonja V Sorenson7the Canadian Expert PanelDivision of Infectious Diseases, Department of Medicine, McMaster University, Hamilton, Ontario, CanadaCenter for Health Economics, Epidemiology and Science Policy, United BioSource Corporation, Maryland, USADepartment of Microbiology-Infectious Diseases, Hospital Maisonneauve-Rosemont, University of Montreal, Montreal, Quebec, CanadaDivision of Infectious Diseases, University of Ottawa, Ottawa, Ontario, CanadaDepartment of Internal Medicine and Medical Microbiology, University of Manitoba, CanadaPfizer Canada Inc, Montreal, Quebec, CanadaPfizer Inc, CanadaCenter for Health Economics, Epidemiology and Science Policy, United BioSource Corporation, Maryland, USABACKGROUND: Candidemia is a common cause of nosocomial bloodstream infection. When selecting therapeutic treatments for candidemia, cost-effectiveness is an important consideration. The present study assessed the cost-effectiveness of voriconazole for the treatment of candidemia.http://dx.doi.org/10.1155/2008/161835 |
| spellingShingle | Coleman Rotstein Lael Cragin Michel Laverdière Gary Garber Eric J Bow Alissa Scalera Craig Roberts Sonja V Sorenson the Canadian Expert Panel Economic Evaluation of Voriconazole for the Treatment of Candidemia in Canadian Adults Canadian Journal of Infectious Diseases and Medical Microbiology |
| title | Economic Evaluation of Voriconazole for the Treatment of Candidemia in Canadian Adults |
| title_full | Economic Evaluation of Voriconazole for the Treatment of Candidemia in Canadian Adults |
| title_fullStr | Economic Evaluation of Voriconazole for the Treatment of Candidemia in Canadian Adults |
| title_full_unstemmed | Economic Evaluation of Voriconazole for the Treatment of Candidemia in Canadian Adults |
| title_short | Economic Evaluation of Voriconazole for the Treatment of Candidemia in Canadian Adults |
| title_sort | economic evaluation of voriconazole for the treatment of candidemia in canadian adults |
| url | http://dx.doi.org/10.1155/2008/161835 |
| work_keys_str_mv | AT colemanrotstein economicevaluationofvoriconazoleforthetreatmentofcandidemiaincanadianadults AT laelcragin economicevaluationofvoriconazoleforthetreatmentofcandidemiaincanadianadults AT michellaverdiere economicevaluationofvoriconazoleforthetreatmentofcandidemiaincanadianadults AT garygarber economicevaluationofvoriconazoleforthetreatmentofcandidemiaincanadianadults AT ericjbow economicevaluationofvoriconazoleforthetreatmentofcandidemiaincanadianadults AT alissascalera economicevaluationofvoriconazoleforthetreatmentofcandidemiaincanadianadults AT craigroberts economicevaluationofvoriconazoleforthetreatmentofcandidemiaincanadianadults AT sonjavsorenson economicevaluationofvoriconazoleforthetreatmentofcandidemiaincanadianadults AT thecanadianexpertpanel economicevaluationofvoriconazoleforthetreatmentofcandidemiaincanadianadults |